Drug Trial Radar · NCT07862582
RYZ711 Diagnostic Platform Study
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
116
Planned (sponsor's estimate)
Start
Oct 5, 2026
Primary completion
Dec 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- RayzeBio, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 7, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1/2 multicenter, multi-cohort imaging study to evaluate the safety, tolerability, and diagnostic performance of RYZ711 positron emission tomography/computed tomography (PET/CT) in men with histologically confirmed adenocarcinoma of the prostate.
Conditions
- Prostate Cancer (Adenocarcinoma)
- Adenocarcinoma of the Prostate
- Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
- Biochemical Recurrence (BCR)
- High-Risk Localized Prostate Cancer
Interventions
RYZ711Drug
RYZ711 PET/CT; PSMA PET/CT
PSMA PET/CTDiagnostic test
RYZ711 PET/CT; PSMA PET/CT
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of AEs, SAEs, and Adverse Events of Special Interest (AESIs)Time frame: From informed consent up to 3 months post-RYZ711 PET/CT
- Concordance Rate of RYZ711 PET/CT Compared with PSMA PET/CTTime frame: Up to 3 months post-RYZ711 PET/CT
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Research Facility
Omaha, Nebraska · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.